## Amendment to the Claims:

This listing of claims will replace all previous versions, and listings, of claims in this application.

## **Listing of Claims:**

Claim 1 (original): A compound in accord with formula I:

$$Q_Ar^1-A_Ar^2$$

I:

and pharmaceutically-acceptable salts thereof, wherein:

Q is a moiety of formula II

II;

-A- is selected from -O-, -S-, or -NR<sup>1</sup>-, or is a bond directly connecting Ar<sup>1</sup> and Ar<sup>2</sup>; Ar<sup>1</sup> is selected from formula III or IV:

wherein B is O, S, or NR<sup>1</sup>;

R<sup>1</sup> is independently at each occurrence selected from hydrogen or R<sup>3</sup>;

D is independently at each occurrence selected from N or CR<sup>2</sup>, provided that D is N at no more than two occurrences;

 $R^2$  is independently at each occurrence selected from hydrogen,  $-R^3$ ,  $-C_2$ - $C_6$ alkenyl,  $-C_2$ - $C_6$ alkynyl, halogen, -CN,  $-NO_2$ ,  $-C(O)R^4$ ,  $-S(O)_nR^5$ ,  $-NR^6R^7$ ,  $-OR^8$ , Q or a bond, provided that  $R^2$  is Q at one occurrence, and at one occurrence is a bond connecting  $Ar^1$  to A, or when -A- is a bond, to  $Ar^2$ ;

 $R^3$  is selected from an unsubstituted straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group, or selected from a straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group substituted with up to five halogen atoms, and up to two substituents selected from:  $C_2$ - $C_6$ alkenyl,  $C_2$ - $C_6$ alkynyl, -CN, -C(O) $R^4$ , -S(O) $_nR^5$ , -NR $^6R^7$ , or -OR $^8$ ;

R<sup>4</sup> is independently at each occurrence selected from hydrogen, R<sup>9</sup>, -NR<sup>10</sup>R<sup>11</sup>, or -OR<sup>8</sup>; R<sup>5</sup> is independently at each occurrence selected from hydrogen, R<sup>9</sup>, or -NR<sup>10</sup>R<sup>11</sup>;

 $R^6$  and  $R^7$  are independently at each occurrence selected from hydrogen,  $R^9$ ,  $-C(O)R^4$  or  $-S(O)_nR^5$ , or in combination at any one occurrence of  $-NR^6R^7$  are  $(CH_2)_pG(CH_2)_q$  where G is O, S,  $NR^8$  or a bond;

R<sup>8</sup> is selected from hydrogen or R<sup>9</sup>;

 $R^9$  is selected from an unsubstituted straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group, or selected from a straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group substituted with up to five halogen atoms, and up to one substituent selected from:  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$ alkynyl, -CN, - $NR^{10}R^{11}$  - $OR^{12}$ ;

 $R^{10}$  and  $R^{11}$  are independently at each occurrence selected from hydrogen,  $R^{12}$ ,  $-C(O)R^{12}$ ,  $-S(O)_nR^{12}$ , or in combination at any one occurrence of  $-NR^{10}R^{11}$  are  $(CH_2)_pJ(CH_2)_q$  where J is O, S, NH,  $NR^{12}$  or a bond;

 $R^{12}$  is selected from an unsubstituted straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group, or selected from a straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group substituted with up to five halogen atoms;

Ar<sup>2</sup> is selected from an unsubstituted 5- or 6-membered aromatic or heteroaromatic ring containing zero to two nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms, or selected from an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to three nitrogen atoms, zero to one oxygen atom, and zero to one sulfur atom, or is selected from a 5- or 6-membered aromatic or heteroaromatic ring containing zero to two nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms, or is selected from an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to three nitrogen atoms, zero to one oxygen atom, and zero to one sulfur atom where each foregoing Ar<sup>2</sup> moiety may bear one to three substituents selected from R<sup>3</sup>, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, halogen, -CN, -NO<sub>2</sub>, -C(O)R<sup>4</sup>, -S(O)<sub>n</sub>R<sup>5</sup>, -NR<sup>6</sup>R<sup>7</sup>, -OR<sup>8</sup>;

n at each occurrence is 0, 1, or 2; p at each occurrence is 2, 3, or 4; q at each occurrence is 0, 1, or 2.

Claim 2 (currently amended): A compound according to Claim 1, wherein:

Ar<sup>1</sup> is selected from formula III or IV:

B is O, S, or NR<sup>1</sup>;

R<sup>1</sup> is independently at each occurrence selected from hydrogen or R<sup>3</sup>;

D is independently at each occurrence selected from N or CR<sup>2</sup>, provided that D is N at two occurrences;

 $R^2$  is independently at each occurrence selected from hydrogen,  $-R^3$ , halogen, -CN,  $-NO_2$ ,  $-C(O)R^4$ ,  $-S(O)_nR^5$ ,  $-NR^6R^7$ ,  $-OR^8$ , Q or a bond, provided that  $R^2$  is Q at one occurrence, and at one occurrence is a bond connecting  $Ar^1$  to A, or when -A- is a bond, to  $Ar^2$ ;

 $R^3$  is an unsubstituted straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group, or a straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group substituted with up to five halogen atoms, and up to two substituents selected from: -CN, -C(O)R<sup>4</sup>, -S(O)<sub>n</sub>R<sup>5</sup>, -NR<sup>6</sup>R<sup>7</sup>, or -OR<sup>8</sup>;

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> are independently at each occurrence selected from hydrogen or R<sup>9</sup>;

 $R^9$  is selected from an unsubstituted straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group, or is selected from a straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group substituted with up to five halogen atoms, and up to one substituent selected from: -CN, -NR<sup>10</sup>R<sup>11</sup> -OR<sup>12</sup>;

R<sup>10</sup> and R<sup>11</sup> are at each occurrence hydrogen;

 $R^{12}$  is selected from an unsubstituted straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group, or selected from a straight-chained, branched, or cyclic  $C_1$ - $C_6$ alkyl group substituted with up to five halogen atoms;

-A- is selected from -O-, -S-, or -NR<sup>1</sup>-, or is a bond directly connecting Ar<sup>1</sup> and Ar<sup>2</sup>;

Ar² is selected from unsubstituted phenyl; 2-pyridyl, 3-pyridyl or 4-pyridyl; 2-pyrimidyl, 4-pyrimidyl or 5-pyrimidyl; 2-pyrazinyl or 3-pyrazinyl; 2-furyl or 3-furyl; 2-thiophenyl or 3-thiophenyl; 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl; 2-quinazolyl, 4-quinazolyl or 5-quinazolyl; 2-oxazolyl, 4-oxazolyl or 5-oxazolyl; 2-imidazolyl, 4-imidazolyl or 5-imidazolyl; 1-naphthyl or 2-naphthyl; 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl or 8-quinolyl; 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl; 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl or 8-isoquinolyl; 2-benzofuranyl, 3-benzofuranyl, 4-benzofuranyl, 5-benzofuranyl, 6-benzofuranyl or 7-benzofuranyl, 4-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl or 7-benzo[b]thiophenyl; 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl or 7-indolyl; 2-benzoxazolyl, 4-benzoxazolyl, 5-benzoxazolyl, 6-benzoxazolyl; or 7-benzoxazolyl; 2-benzthiazolyl, 4-benzthiazolyl, 5-benzthiazolyl, 6-benzthiazolyl or 7-benzthiazolyl; or is selected from any foregoing Ar² moiety substituted with one to three substituents selected from R³, C2-C6 alkenyl, C2-C6 alkynyl, halogen, -CN, -NO2, -C(O)R⁴, -S(O)nR⁵, -NR⁶R७, -OR⁶;

n at each occurrence is 0, 1, or 2.

Claim 3 (currently amended): A compound according to Claim 1, wherein: R<sup>2</sup> is Q at one occurrence and is a bond connecting Ar<sup>1</sup> to A at one occurrence and otherwise is hydrogen.

Claim 4 (original): A compound according to Claim 1, wherein Q and -A-Ar<sup>2</sup> are in a 1,3 relationship with one another on Ar<sup>1</sup>.

Claim 5 (currently amended): A compound according to Claim 1, wherein -A- is a bond directly occurrence Ar<sup>1</sup> and Ar<sup>2</sup>.

Claim 6 (original): A compound according to Claim 1, wherein Ar<sup>1</sup> is a moiety of formula III.

Claim 7 (original): A compound according to Claim 1 wherein Ar<sup>1</sup> is selected from a furan ring or a thiophene ring.

Claim 8 (original): A compound according to Claim 1, wherein Ar<sup>1</sup> is a moiety of formula III and B is selected from O or S.

Claim 9 (original): A compound according to Claim 1, wherein Ar<sup>1</sup> is a moiety of formula III and B is S.

Claim 10 (currently amended): A compound according to Claim 1, wherein Ar<sup>1</sup> is a moiety of formula III and D is CR<sup>2</sup> where R<sup>2</sup> is Q at one occurrence and is a bond connecting Ar<sup>1</sup> to A at one occurrence and otherwise is hydrogen.

Claim 11 (original): A compound according to Claim 1, wherein R<sup>3</sup> is selected from: methyl, ethyl,

linear, cyclic or branched propyl, butyl, pentyl or hexyl,

ethenyl or 1-propenyl, 2-propenyl or 3-propenyl,

linear, branched or cyclic butenyl, pentenyl or hexenyl,

ethynyl or propynyl,

chloro, bromo, fluoro or iodo, -CN, -NO<sub>2</sub>, -C(O)R<sup>4</sup>, -S(O)<sub>n</sub>R<sup>5</sup>, -NR<sup>6</sup>R<sup>7</sup> or -OR<sup>8</sup>;

R<sup>4</sup> is independently at each occurrence selected from hydrogen, R<sup>9</sup>, -NR<sup>10</sup>R<sup>11</sup>, -OR<sup>8</sup> trifluoromethyl, trifluoromethyl, methoxymethyl, trifluoromethoxymethyl, methoxymethyl or trifluoromethoxyethyl;

 $R^5$  is independently at each occurrence selected from hydrogen,  $R^9$ , or -NR  $^{10}R^{11}$ ;

 $R^6$  and  $R^7$  are independently at each occurrence selected from hydrogen,  $R^9$ ,  $-C(O)R^4$ ,  $-S(O)_nR^5$ , or in combination at any one occurrence of  $-NR^6R^7$  are  $(CH_2)_pG(CH_2)_q$  where G is O, S,  $NR^8$  or a bond;

R<sup>8</sup> is selected from hydrogen or R<sup>9</sup>;

R<sup>9</sup> is selected from

methyl, ethyl,

linear, cyclic or branched propyl, butyl, pentyl or hexyl

ethenyl or 1-propenyl, 2-propenyl or 3-propenyl

linear, branched or cyclic butenyl, pentenyl or hexenyl,

ethynyl or propynyl,

where any foregoing R<sup>9</sup> moiety may bear up to five chloro, bromo, fluoro or iodo atoms, and up to one substituent selected from:

-CN,  $-NR^{10}R^{11} - OR^{12}$ ;

 $R^{10}$  and  $R^{11}$  are independently at each occurrence selected from hydrogen,  $R^{12}$ ,  $-C(O)R^{12}$ ,  $-S(O)_nR^{12}$ , or in combination at any one occurrence of  $-NR^{10}R^{11}$  are  $(CH_2)_pJ(CH_2)_q$  where J is O, S, NH,  $NR^{12}$  or a bond;

 $R^{12}$  is

methyl, ethyl,

linear, cyclic or branched propyl, butyl, pentyl or hexyl

ethenyl or 1-propenyl, 2-propenyl or 3-propenyl

linear, branched or cyclic butenyl, pentenyl or hexenyl,

ethynyl or propynyl,

where any foregoing R<sup>12</sup> moiety may bear up to five chloro, bromo, fluoro, iodo atoms,

Ar² is selected from unsubstituted phenyl; 2-pyridyl, 3-pyridyl or 4-pyridyl; 2-pyrimidyl, 4-pyrimidyl or 5-pyrimidyl; 2-pyrazinyl or 3-pyrazinyl; 2-furyl or 3-furyl; 2-thiophenyl or 3-thiophenyl; 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl; 2-quinazolyl, 4-quinazolyl or 5-quinazolyl; 2-oxazolyl, 4-oxazolyl or 5-oxazolyl; 2-imidazolyl, 4-imidazolyl or 5-imidazolyl; 1-naphthyl or 2-naphthyl; 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl or 8-quinolyl, 3-isoquinolyl, 4-isoquinolyl; 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl or 8-isoquinolyl; 2-benzofuranyl, 3-benzofuranyl, 4-benzofuranyl, 5-benzofuranyl, 6-benzofuranyl or 7-benzofuranyl, 2-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-indolyl, 6-indolyl or 7-indolyl; 2-benzoxazolyl, 4-benzoxazolyl, 5-benzoxazolyl, 6-benzoxazolyl; or 7-benzoxazolyl; 2-benzthiazolyl, 4-benzthiazolyl, 5-benzthiazolyl, 6-benzthiazolyl or 7-benzthiazolyl; or any foregoing Ar² moiety substituted with 1, 2 or 3 R³ substituents.

```
Claim 12 (original): A compound according to Claim 1, selected from:
(R)-3'-(5-phenyl-thiophen-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(4-pyridyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(3-pyridyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(2-pyridyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiophen-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiophen-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(furan-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(furan-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiazol-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiazol-4-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiazol-5-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(4-phenylthiophen-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(4-pyridyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(3-pyridyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(2-pyridyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiophen-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiophen-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(furan-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(furan-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiazol-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiazol-4-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiazol-5-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(2-phenylthiophen-4-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(4-pyridyl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(3-pyridyl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(2-pyridyl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(thiophen-2-yl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(thiophen-3-yl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(furan-2-yl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
```

```
(R)-3'-[2-(furan-3-yl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3.5'-oxazolidin]-2'-one:
(R)-3'-[2-(thiazol-2-yl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(thiazol-4-yl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(thiazol-5-yl)thiophen-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(5-phenylfuran-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(4-pyridyl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(3-pyridyl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(2-pyridyl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiophen-2-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiophen-3-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(furan-2-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(furan-3-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiazol-2-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiazol-4-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(thiazol-5-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(4-phenylfuran-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(4-pyridyl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(3-pyridyl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(2-pyridyl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiophen-2-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiophen-3-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(furan-2-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(furan-3-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiazol-2-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiazol-4-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(thiazol-5-yl)furan-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(2-phenylfuran-4-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(4-pyridyl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(3-pyridyl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(2-pyridyl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
```

- (R)-3'-[2-(thiophen-2-yl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[2-(thiophen-3-yl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[2-(furan-2-yl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[2-(furan-3-yl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[2-(thiazol-2-yl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[2-(thiazol-4-yl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one, or
- (R)-3'-[2-(thiazol-5-yl)furan-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one, or a pharmaceutically-acceptable salt thereof.

Claim 13 (original): A compound according to Claim 1, selected from:

- (R)-3'-{5-[3-(N,N-dimethylcarbamoyl)phenyl]thiophen-2-yl}spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-{5-[3-(N,N-diethylcarbamoyl)phenyl]thiophen-2-yl}spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-{5-[3-(pyrrolidine-1-carbonyl)phenyl]thiophen-2-yl}spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-{5-[3-(piperidine-1-carbonyl)phenyl]thiophen-2-yl}spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (*R*)-3'-{5-[3-(morpholine-4-carbonyl)phenyl]thiophen-2-yl}spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R) 3' [5 (3-aminophenyl) thiophen 2 yl] spiro [1-azabicyclo [2.2.2] octan 3,5' oxazolidin] 2' one;
- (R)-3'-{5-[3-(N,N-dimethylamino)phenyl]thiophen-2-yl}spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-{5-[3-(propionylamino)phenyl]thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-{5-[3-(butyrylamino)phenyl]thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-{5-[3-(benzoylamino)phenyl]thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;

```
(R)-3'-{5-[3-(2-propoxy)phenyl]thiophen-2-yl}spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-
2'-one;
(R)-3'-[5-(3-trifluoromethoxyphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-
oxazolidin]-2'-one;
(R)-3'-[5-(quinolin-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(quinolin-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(quinolin-4-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3.5'-oxazolidin]-2'-one;
(R)-3'-[5-(quinolin-5-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(quinolin-6-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(quinolin-7-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(quinolin-8-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(pyrimidin-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(pyrimidin-4-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(pyrimidin-5-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(2-phenylthiazol-4-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(2-pyridyl)thiazol-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(3-pyridyl)thiazol-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(4-pyridyl)thiazol-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(2-phenylthiazol-5-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(2-pyridyl)thiazol-5-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(3-pyridyl)thiazol-5-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(4-pyridyl)thiazol-5-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(2-pyridyl)-1,3,4-thiadiazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(3-pyridyl)-1,3,4-thiadiazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(5-phenyl-1,3,4-oxadiazol-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(5-phenyloxazol-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(2-pyridyl)oxazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(3-pyridyl)thiazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(4-pyridyl)thiazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(4-phenyloxazol-2-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
```

```
(R)-3'-[4-(3-pyridyl)thiazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[4-(4-pyridyl)thiazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(2-phenyloxazol-4-yl)spiro[1-azabicyclo[2.2.2]octan-3.5'-oxazolidin]-2'-one:
(R)-3'-[2-(2-pyridyl)oxazol-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(3-pyridyl)thiazol-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(4-pyridyl)thiazol-4-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-(2-phenyloxazol-5-yl)spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(2-pyridyl)oxazol-5-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(3-pyridyl)thiazol-5-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[2-(4-pyridyl)thiazol-5-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(2-pyridyl)-1,3,4-oxadiazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(3-pyridyl)-1,3,4-oxadiazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
and
(R)-3'-[5-(4-pyridyl)-1,3,4-oxadiazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
Claim 14 (original): A compound according to Claim 1, selected from:
(R)-3'-[5-(2-fluorophenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(3-fluorophenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(4-fluorophenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(2-chlorophenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(3-chlorophenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(4-chlorophenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(3,4-dichlorophenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-
one;
(R)-3'-[5-(3-methylphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(4-methylphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
(R)-3'-[5-(3-methoxyphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-
one;
```

(R)-3'-[4-(2-pyridyl)oxazol-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;

- (R)-3'-[5-(4-methoxyphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(3-methoxyphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(3-trifluoromethylphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(4-trifluoromethylphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(3-trifluoromethoxyphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(4-trifluoromethoxyphenyl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(naphthalen-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(benzofuran-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(benzo[b]thiophen-2-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(2-fluoropyridin-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one:
- (R)-3'-[5-(2-chloropyridin-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(2-methoxypyridin-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(2-aminopyridin-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'- $\{5-[2-(N,N-dimethylamino)pyridin-3-yl]$ thiophen-2-yl $\}$ spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(5-chloropyridin-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;
- (R)-3'-[5-(5-methoxypyridin-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one;

(R)-3'-[5-(5-aminopyridin-3-yl)thiophen-2-yl]spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one; and

(R)-3'- $\{5-[5-(N,N-dimethylamino)pyridin-3-yl]$ thiophen-2-yl $\}$  spiro[1-azabicyclo[2.2.2]octan-3,5'-oxazolidin]-2'-one.

Claim 15 (original): A compound according to Claim 1, wherein one or more of the atoms of said compound is a radioisotope of said atom.

Claim 16 (original): A compound according to Claim 15, wherein the radioisotope is tritium.

Claim 17 (original): A method for the discovery of novel medicinal compounds which bind to and modulate the activity, by agonism, partial agonism, or antagonism, of the  $\alpha$ 7 nicotinic acetylcholine receptor comprising measuring the displacement of a compound according to Claim 15 from an  $\alpha$ 7 nicotinic acetylcholine receptor

Claim 18 (currently amended): A method of treatment or prophylaxis of a human disease or condition in which activation of the α7 nicotinic receptor is beneficial which comprises administering a therapeutically-effective amount of a compound according to Claim 1.

Claim 19 (original): The method of Claim 18, wherein said human disease or condition is selected from neurological disorders, psychotic disorders or intellectual impairment disorders.

Claim 20 (original): The method of Claim 18, wherein said human disease or condition is selected from Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapses, anxiety, schizophrenia, mania or manic depression.

Claim 21 (original): A method of treatment for jetlag, inducing cessation of smoking, nicotine addiction, craving, pain, and for ulcerative colitis, which comprises administering a therapeutically effective amount of a compound according to Claim 1.

Claim 22 (original): A pharmaceutical composition comprising a compound according to Claim 1, an enantiomer thereof or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.

Claim 23 (original): A method of treating or preventing a condition or disorder arising from dysfunction of nicotinic acetylcholine receptor neurotransmission in a mammal comprising administering a therapeutically effective amount of a pharmaceutical composition according to Claim 22, to said mammal effective in treating or preventing such disorder or condition.

Claim 24 (original): A method for the treatment or prophylaxis of a human disease or condition in which activation of the α7 nicotinic receptor is beneficial comprising administering a therapeutically effective amount of a pharmaceutical composition according to Claim 22.

Claim 25 (original): The method of Claim 24, wherein said human disease or condition is selected from: neurological disorders, psychotic disorders or intellectual impairment disorders.

Claim 26 (original): The method of Claim 25, wherein said human disease or condition is selected from: Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania, manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and ulcerative colitis.

Claims 27 - 29 (canceled).